CD8A and cancer: For the monitoring of MRD and effective T cell responses, it is important that proteins specific to the disease are identified and for immunotherapy that cancer specific antigens are the targets of immune responses, including those enacted by B-cell responses (by definition) and their immune counterparts (CD4+ and CD8+ T-cells among others).